Sever drug eruption induced by sintilimab
10.3760/cma.j.cn114015-20220216-00128
- VernacularTitle:信迪利单抗致重度药疹
- Author:
Danxing TIAN
1
Author Information
1. 浙江省立同德医院中医内科，杭州 310012
- Publication Type:Journal Article
- Keywords:
Programmed cell death 1 receptor;
Drug eruptions;
Sintilimab
- From:
Adverse Drug Reactions Journal
2022;24(10):554-556
- CountryChina
- Language:Chinese
-
Abstract:
A 67-year-old male patient received immunotherapy with intravenous infusion of sintili-mab 200 mg once every 3 weeks due to postoperative recurrence of liver cancer, and the efficacy and tolerance was good. After 12 doses of sintilimab treatment, the patient developed a bright red skin rashes on the chest, abdomen, and extremities with itching. Oral loratadine and topical halometasone cream were given, and the rashes were improved slightly. The rashes did not spread in the next 2 doses of sintilimab treatment. But after the 3rd dose of continuing sintilimab, the patient suddenly developed a large-area rashes all over the body, which rapidly developed into blisters, ulcers, accompanied by oozing blood and fluid on the skin, itching, and pain. Drug eruptions were diagnosed, which was considered to be induced by sintilimab. The drug was stopped. After 1 week of treatments with intravenous infusion of methylprednisolone 60 mg once daily, anti-allergy, anti-infection, mucosal protection, and skin care, the rashes were repeated. Then the dose of methylprednisolone was increased, the rashes were still not relieved 1 week later, and gastrointesting bleeding occurred. After liver cancer surgery, the patient was accompanied by hypoproteinemia, liver dysfunction, and long-term high-dose glucocorticoid use. Therefore, despite active treatment measures, the patient still died of ineffective rescue.
